| Naslov: | Novel perspectives of testosterone therapy in men with functional hypogonadism |
|---|
| Avtorji: | ID Groti Antonič, Kristina (Avtor)
ID Zitzmann, Michael (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (1,19 MB)
MD5: E19820BEF304B2ADAEF243197CEC49D0
 URL - Izvorni URL, za dostop obiščite https://www.tandfonline.com/doi/full/10.1080/13685538.2023.2296460
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.02 - Pregledni znanstveni članek |
|---|
| Organizacija: |  UKC LJ - Univerzitetni klinični center Ljubljana
|
|---|
| Povzetek: | Introduction In the past decade, there has been a significant augmentation in the corpus of evidence pertaining to functional hypogonadism. Despite this, prevailing clinical guidelines continue to advise against the universal screening for hypogonadism in middle-aged and elderly males. Findings Numerous randomized controlled trials have scrutinized the effects of testosterone therapy in males afflicted with type 2 diabetes and/or obesity. However, these guidelines uniformly assert that lifestyle modifications and weight reduction should be the primary intervention strategies in overweight and obese males, relegating testosterone therapy to a secondary, selective option. It is extensively documented that testosterone therapy can yield substantial improvements in various metabolic parameters as well as ameliorate symptoms of erectile dysfunction. Moreover, recent studies have demonstrated the potential of testosterone therapy in reversing type 2 diabetes in males with low-normal testosterone levels who are at elevated risk for this condition, in comparison to the outcomes achievable through lifestyle modifications alone. Conclusion This focused review article aims to present a comprehensive update on the latest data concerning the innovative aspects of testosterone therapy in males with functional hypogonadism, particularly in the context of type 2 diabetes and/or obesity. Additionally, it will delve into the cardiovascular safety of such interventions within this high-risk demographic, with a special emphasis on insights gleaned from the TRAVERSE trial. |
|---|
| Ključne besede: | hypogonadism, testosterone, men hypogonadism |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Leto izida: | 2024 |
|---|
| Št. strani: | 14 str. |
|---|
| Številčenje: | Vol. 27, no. 1, [article no.] 2296460 |
|---|
| PID: | 20.500.12556/DiRROS-28114  |
|---|
| UDK: | 616.4 |
|---|
| ISSN pri članku: | 1473-0790 |
|---|
| DOI: | 10.1080/13685538.2023.2296460 |
|---|
| COBISS.SI-ID: | 242345987 |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Opis vira z dne 13. 7. 2025;
|
|---|
| Datum objave v DiRROS: | 10.03.2026 |
|---|
| Število ogledov: | 88 |
|---|
| Število prenosov: | 63 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
